Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vildagliptin + pioglitazone
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**vildagliptin + pioglitazone** is a fixed-dose oral combination of two small molecule antidiabetic agents used for the management of type 2 diabetes mellitus. Vildagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing degradation of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon levels. Pioglitazone is an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that modulates the transcription of genes involved in glucose and lipid metabolism, improving insulin sensitivity in peripheral tissues. The combination provides complementary mechanisms to improve glycemic control as first-line or add-on therapy when monotherapy is insufficient. It is mainly indicated for adults with type 2 diabetes and is available in tablet form[1][3][5][6].
- Brand names
- VILDIABATE PIO
- Other names
- pioglitazone + vildagliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on vildagliptin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vildagliptin + pioglitazone.